Evidence map›Paper›PMID 41976838›Full record

ArticleJournal of clinical medicine2026

Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical Studies.

Ari Zimran, Jaco Botha, Richard Eastell, Can Ficicioglu, Richard D Finkelman, Dafna Frydman, Pilar Giraldo, Ozlem Goker-Alpan, Priya S Kishnani, Heather Lau and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ari ZimranGaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.ORCID 0000-0003-0077-8608
Jaco BothaTakeda Pharmaceuticals International AG, 8152 Opfikon, Switzerland.
Richard EastellAcademic Unit of Bone Metabolism, University of Sheffield, Sheffield S5 7AU, UK.ORCID 0000-0002-0323-3366
Can FiciciogluDivision of Human Genetics and Metabolism, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-8331-9804
Richard D FinkelmanTakeda Development Center Americas, Inc., Cambridge, MA 02142, USA.
Dafna FrydmanGaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.ORCID 0009-0007-3398-7584
Pilar GiraldoTranslational Research Unit, IIS Aragon, 50009 Zaragoza, Spain.ORCID 0000-0002-8791-1901
Ozlem Goker-AlpanLysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA 22030, USA.ORCID 0000-0003-4758-6793
Priya S KishnaniDivision of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
Heather LauDepartment of Internal Medicine, University of Yale, New Haven, CT 06520, USA.ORCID 0000-0003-1690-9457
Noa Ruhrman-ShaharThe Raphael Recanati Genetics Institute, Rabin Medical Center-Beilinson Hospital, Petah Tikva 49100, Israel.ORCID 0009-0009-8725-2596
Derralynn A HughesLysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust, University College London, London NW3 2QG, UK.ORCID 0000-0003-4531-9173

Funding

Takeda Development Center Americas, Inc. Takeda Development Center Americas, Inc.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bone marrow burdenbone mineral densityenzyme replacement therapyGaucher diseaseglucocerebrosidasevelaglucerase alfa

Identifiers

PMID41976838
PMCPMC13073715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.